Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Dec 15;63(suppl 5):S312-S321.
doi: 10.1093/cid/ciw631.

Pre-referral Rectal Artesunate Treatment by Community-Based Treatment Providers in Ghana, Guinea-Bissau, Tanzania, and Uganda (Study 18): A Cluster-Randomized Trial

Collaborators, Affiliations
Randomized Controlled Trial

Pre-referral Rectal Artesunate Treatment by Community-Based Treatment Providers in Ghana, Guinea-Bissau, Tanzania, and Uganda (Study 18): A Cluster-Randomized Trial

Marian Warsame et al. Clin Infect Dis. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Clin Infect Dis. 2017 May 15;64(10):1469. doi: 10.1093/cid/ciw874. Clin Infect Dis. 2017. PMID: 28329115 Free PMC article. No abstract available.

Abstract

Background: If malaria patients who cannot be treated orally are several hours from facilities for injections, rectal artesunate prior to hospital referral can prevent death and disability. The goal is to reduce death from malaria by having rectal artesunate treatment available and used. How best to do this remains unknown.

Methods: Villages remote from a health facility were randomized to different community-based treatment providers trained to provide rectal artesunate in Ghana, Guinea-Bissau, Tanzania, and Uganda. Prereferral rectal artesunate treatment was provided in 272 villages: 109 through community-based health workers (CHWs), 112 via trained mothers (MUMs), 25 via trained traditional healers (THs), and 26 through trained community-chosen personnel (COMs); episodes eligible for rectal artesunate were established through regular household surveys of febrile illnesses recording symptoms eligible for prereferral treatment. Differences in treatment coverage with rectal artesunate in children aged <5 years in MUM vs CHW (standard-of-care) villages were assessed using the odds ratio (OR); the predictive probability of treatment was derived from a logistic regression analysis, adjusting for heterogeneity between clusters (villages) using random effects.

Results: Over 19 months, 54 013 children had 102 504 febrile episodes, of which 32% (31 817 episodes) had symptoms eligible for prereferral therapy; 14% (4460) children received treatment. Episodes with altered consciousness, coma, or convulsions constituted 36.6% of all episodes in treated children. The overall OR of treatment between MUM vs CHW villages, adjusting for country, was 1.84 (95% confidence interval [CI], 1.20-2.83; P = .005). Adjusting for heterogeneity, this translated into a 1.67 higher average probability of a child being treated in MUM vs CHW villages. Referral compliance was 81% and significantly higher with CHWs vs MUMs: 87% vs 82% (risk ratio [RR], 1.1 [95% CI, 1.0-1.1]; P < .0001). There were more deaths in the TH cluster than elsewhere (RR, 2.7 [95% CI, 1.4-5.6]; P = .0040).

Conclusions: Prereferral episodes were almost one-third of all febrile episodes. More than one-third of patients treated had convulsions, altered consciousness, or coma. Mothers were effective in treating patients, and achieved higher coverage than other providers. Treatment access was low.

Clinical trials registration: ISRCTN58046240.

Keywords: Africa; CHWs; coverage; mothers; rectal artesunate.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Trial profile of clusters and participants.
Figure 2.
Figure 2.
Coverage: odds ratios (ORs) and 95% confidence intervals (CIs) for treatment, mother (MUM) vs community health worker (CHW) clusters.
Figure 3.
Figure 3.
Coverage: adjusted predicted probability ratio of treatment (odds ratios [ORs] and confidence intervals [CIs]), mother (MUM) vs community health worker (CHW) clusters.

References

    1. Dondorp A, Nosten F, Stepniewska N, Day NP, White NJ. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717–25. - PubMed
    1. Dondorp AM, Fanello CI, Hendriksen ICE et al. . Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647–57. - PMC - PubMed
    1. Gomes MF, Faiz MA, Gyapong JO et al. . Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 2009; 373:557–66. - PMC - PubMed
    1. Bahl R, Qazi S, Darmstadt GL, Martines J. Why is continuum of care from home to health facilities essential to improve perinatal survival? Semin Perinatol 2010; 34:477–85. - PubMed
    1. World Health Organization. WHO guidelines for the treatment of malaria. 3rd ed Geneva, Switzerland: WHO, 2015.

Publication types